tirzepatide for menopause weight gain plus hormone therapy aids loss GLP-1 for Menopause Weight Gain:

Tirzepatide is a dual GLP-1 and GIP agonist, and semaglutide is a GLP-1 agonist

However, gastrointestinal side effects from semaglutide could theoretically reduce DOAC absorption, so report nausea or vomiting to your doctor promptly

Slight increase in muscle mass

Food and Drug Administration (FDA): Ozempic (semaglutide) Injection Prescribing Information National Institutes of Health (NIH): The Physiology of Ketosis and Its Impact on Breath Volatiles American Gastroenterological Association (AGA): Understanding Delayed Gastric Emptying and GLP-1 Receptor Agonists Mayo Clinic: Symptoms and Causes of Halitosis and Body Odor Changes Community Anecdotal Reference: Reddit Ozempic Community Discussion on Sweat and Odor Changes (Included for patient-reported symptom-pattern context)

Understanding the Risks Some of the factors that may increase the likelihood of Ozempic or Wegovy eye side effects include: Existing diabetes-related eye conditions (like retinopathy) Pre-existing vision problems Dosage and length of use Especially for diabetic patients taking these medications, communication with your ophthalmologist is critical